0001843714 2026-01-01 2026-03-31 0001843714 2026-03-31 0001843714 2025-12-31 0001843714 ZPAT:SeriesAConvertiblePreferredStockMember 2026-03-31 0001843714 ZPAT:SeriesAConvertiblePreferredStockMember 2025-12-31 0001843714 ZPAT:SeriesCConvertiblePreferredStockMember 2026-03-31 0001843714 ZPAT:SeriesCConvertiblePreferredStockMember 2025-12-31 0001843714 us-gaap:RelatedPartyMember 2026-03-31 0001843714 us-gaap:RelatedPartyMember 2025-12-31 0001843714 2025-01-01 2025-03-31 0001843714 ZPAT:SeriesAAndCConvertiblePreferredStockMember 2025-12-31 0001843714 us-gaap:CommonStockMember 2025-12-31 0001843714 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001843714 ZPAT:AccumulatedOtherComprehensiveLossMember 2025-12-31 0001843714 us-gaap:RetainedEarningsMember 2025-12-31 0001843714 ZPAT:SeriesAAndCConvertiblePreferredStockMember 2024-12-31 0001843714 us-gaap:CommonStockMember 2024-12-31 0001843714 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001843714 ZPAT:AccumulatedOtherComprehensiveLossMember 2024-12-31 0001843714 us-gaap:RetainedEarningsMember 2024-12-31 0001843714 2024-12-31 0001843714 ZPAT:SeriesAAndCConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001843714 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001843714 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001843714 ZPAT:AccumulatedOtherComprehensiveLossMember 2026-01-01 2026-03-31 0001843714 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001843714 ZPAT:SeriesAAndCConvertiblePreferredStockMember 2025-01-01 2025-03-31 0001843714 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001843714 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001843714 ZPAT:AccumulatedOtherComprehensiveLossMember 2025-01-01 2025-03-31 0001843714 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001843714 ZPAT:SeriesAAndCConvertiblePreferredStockMember 2026-03-31 0001843714 us-gaap:CommonStockMember 2026-03-31 0001843714 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001843714 ZPAT:AccumulatedOtherComprehensiveLossMember 2026-03-31 0001843714 us-gaap:RetainedEarningsMember 2026-03-31 0001843714 ZPAT:SeriesAAndCConvertiblePreferredStockMember 2025-03-31 0001843714 us-gaap:CommonStockMember 2025-03-31 0001843714 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001843714 ZPAT:AccumulatedOtherComprehensiveLossMember 2025-03-31 0001843714 us-gaap:RetainedEarningsMember 2025-03-31 0001843714 2025-03-31 0001843714 ZPAT:AccreditedInvestorsMember us-gaap:SeriesDPreferredStockMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 0001843714 ZPAT:SeniorSecuredNotesMember 2026-01-01 2026-03-31 0001843714 ZPAT:SeniorSecuredNotesMember 2026-03-31 0001843714 ZPAT:SeniorSecuredNotesMember 2025-12-31 0001843714 ZPAT:AccreditedInvestorsMember ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2025-06-01 2025-06-30 0001843714 ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2025-06-01 2025-06-30 0001843714 ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2025-06-30 0001843714 ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2026-03-31 0001843714 ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2024-01-01 2024-12-31 0001843714 ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2026-01-01 2026-03-31 0001843714 ZPAT:ConvertiblePromissoryNotesMember ZPAT:PurchaseAgreementMember 2025-01-01 2025-12-31 0001843714 ZPAT:ForbearanceAgreementsMember 2025-01-01 2025-12-31 0001843714 ZPAT:SeriesAConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001843714 ZPAT:SeriesCConvertiblePreferredStockMember 2026-01-01 2026-03-31 0001843714 us-gaap:SeriesAPreferredStockMember 2026-03-31 0001843714 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-03-31 0001843714 us-gaap:SeriesCPreferredStockMember 2026-03-31 0001843714 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-03-31 0001843714 2024-03-26 2024-03-28 0001843714 2024-03-28 0001843714 ZPAT:PublicWarrantsMember us-gaap:CommonStockMember 2026-03-31 0001843714 ZPAT:PrivatePlacementWarrantsMember us-gaap:CommonStockMember 2026-03-31 0001843714 ZPAT:PublicWarrantsMember 2026-01-01 2026-03-31 0001843714 ZPAT:PublicWarrantsMember 2026-03-31 0001843714 ZPAT:PublicWarrantsMember 2025-12-31 0001843714 ZPAT:PrivatePlacementWarrantsMember 2026-03-31 0001843714 ZPAT:PrivatePlacementWarrantsMember 2025-12-31 0001843714 ZPAT:WarrantsMember 2026-01-01 2026-03-31 0001843714 ZPAT:WarrantsMember 2026-03-31 0001843714 us-gaap:WarrantMember 2025-12-31 0001843714 us-gaap:WarrantMember 2025-01-01 2025-12-31 0001843714 us-gaap:WarrantMember 2026-01-01 2026-03-31 0001843714 us-gaap:WarrantMember 2026-03-31 0001843714 us-gaap:StockOptionMember 2025-12-31 0001843714 us-gaap:StockOptionMember 2025-01-01 2025-12-31 0001843714 us-gaap:StockOptionMember 2026-01-01 2026-03-31 0001843714 us-gaap:StockOptionMember 2026-03-31 0001843714 ZPAT:TwentyTwentyFourPlanMember us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001843714 ZPAT:TwentyTwentyFourPlanMember us-gaap:CommonStockMember 2026-03-31 0001843714 ZPAT:ResearchAndDevelopmentExpensesMember 2026-01-01 2026-03-31 0001843714 ZPAT:ResearchAndDevelopmentExpensesMember 2025-01-01 2025-03-31 0001843714 ZPAT:SellingAndMarketingExpensesMember 2026-01-01 2026-03-31 0001843714 ZPAT:SellingAndMarketingExpensesMember 2025-01-01 2025-03-31 0001843714 ZPAT:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-03-31 0001843714 ZPAT:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-03-31 0001843714 us-gaap:SeriesAPreferredStockMember 2026-01-01 2026-03-31 0001843714 us-gaap:SeriesAPreferredStockMember 2025-01-01 2025-03-31 0001843714 us-gaap:SeriesCPreferredStockMember 2026-01-01 2026-03-31 0001843714 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-03-31 0001843714 ZPAT:SeniorSecuredNotesIncludingAccruedInterestMember 2026-01-01 2026-03-31 0001843714 ZPAT:SeniorSecuredNotesIncludingAccruedInterestMember 2025-01-01 2025-03-31 0001843714 ZPAT:ConvertiblePromissoryNotesIncludingAccruedInterestMember 2026-01-01 2026-03-31 0001843714 ZPAT:PublicWarrantsMember 2026-01-01 2026-03-31 0001843714 ZPAT:PublicWarrantsMember 2025-01-01 2025-03-31 0001843714 ZPAT:PrivatePlacementWarrantsMember 2026-01-01 2026-03-31 0001843714 ZPAT:PrivatePlacementWarrantsMember 2025-01-01 2025-03-31 0001843714 ZPAT:UnvestedSharesMember 2026-01-01 2026-03-31 0001843714 ZPAT:UnvestedSharesMember 2025-01-01 2025-03-31 0001843714 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-03-31 0001843714 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-03-31 0001843714 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-03-31 0001843714 us-gaap:RestrictedStockUnitsRSUMember 2025-01-01 2025-03-31 0001843714 us-gaap:SeriesAPreferredStockMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-07 0001843714 ZPAT:ConsultantMember us-gaap:SubsequentEventMember 2026-04-01 2026-04-30 iso4217:USD shares iso4217:USD shares pure false 0001843714 S-1 Zapata Quantum, Inc. DE 98-1578373 6 Liberty Square, #2488 Boston MA 02109 857 367-9002 Non-accelerated Filer true true false 642000 1659000 158000 181000 800000 1840000 404000 432000 1204000 2272000 4070000 3963000 1547000 1764000 406000 406000 300000 300000 3227000 3133000 1311000 1273000 10561000 10539000 0.0001 0.0001 15000 15000 15000 15000 15000 15000 0.0001 0.0001 23000 23000 11983 11983 11983 11983 0.0001 0.0001 600000000 600000000 172318506 172318506 172318506 172318506 17000 17000 110449000 110211000 -180000 -162000 -119643000 -118333000 -9357000 -8267000 1204000 2272000 173000 235000 789000 680000 1197000 680000 -1197000 -680000 132000 102000 19000 12000 -113000 -90000 -1310000 -770000 -1310000 -770000 -0.01 -0.01 -0.02 -0.02 172318506 172318506 42482376 42482376 -1310000 -770000 -18000 -14000 -1328000 -784000 26983 172318506 17000 110211000 -162000 -118333000 -8267000 238000 238000 -1310000 -1310000 -18000 -18000 26983 172318506 17000 110449000 -180000 -119643000 -9357000 43589506 4000 104301000 -109000 -127669000 -23473000 25000 44000 44000 -770000 -770000 -14000 -14000 43614506 4000 104345000 -123000 -128439000 -24213000 -1310000 -770000 132000 525000 238000 44000 -51000 -94000 107000 48000 -217000 -999000 -59000 -18000 -12000 -1017000 -71000 1659000 359000 642000 288000 <p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zwyObG44AH4f" style="font: 9pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #212529"> </p> <table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0px"> </td> <td style="width: 18px"><span style="font-size: 10pt"><b>1.</b></span></td> <td><span style="font-size: 10pt"><b><span id="xdx_82F_zqOXsCxEjIA7">Nature of the Business and Basis of Presentation</span></b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27.7pt">Zapata Quantum, Inc. (the “Company”, “we”, “us”, or “our”), following a strategic realignment in 2025, offers solutions to efficiently deploy and accelerate the development of quantum and hybrid quantum-classical computing applications. These solutions include software and software tools supported by services. Its software platform is based on patented technology and supports a wide range of use cases in cryptography, pharmaceuticals, manufacturing, materials discovery and defense. These planned operations are subject to the Company raising sufficient capital. The Company has worked with Fortune 500 enterprises and government agencies to unlock the potential of quantum computing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">The accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. We believe that the disclosures contained in these condensed financial statements are adequate to make the information presented herein not misleading. These condensed financial statements should be read in conjunction with the financial statements contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 31, 2026 (the “Annual Report”). The accompanying condensed consolidated financial statements are unaudited, and in the opinion of management, contain all adjustments, including normal recurring adjustments, necessary to present fairly the Company’s financial position as of March 31, 2026, and the results of its operations and its cash flows for the three months ended March 31, 2026 and 2025. The balance sheet as of December 31, 2025 is derived from the Company’s audited financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. For the three months ended March 31, 2026, the Company recorded a net loss of $<span id="xdx_908_eus-gaap--NetIncomeLoss_iN_pn3n3_di_c20260101__20260331_zKJbJ4QE2U88" title="Net Income loss">1,310</span>, used cash in operations of $<span id="xdx_900_eus-gaap--NetCashProvidedByUsedInContinuingOperations_pn3n3_c20260101__20260331_zqmZsgVkhfk3" title="Cash in operations">999</span> and had a stockholders’ deficit of $<span id="xdx_90E_eus-gaap--StockholdersEquity_iNI_pn3n3_di_c20260331_zP96j2ZbDMhc" title="Stockholders' deficit">9,357</span> as of that date. As of March 31, 2026, the Company had a cash balance of $<span id="xdx_90B_eus-gaap--Cash_iI_pn3n3_c20260331_zYy72iJeOBV" title="Cash balance">642</span>. Cash used in operations was primarily from the Company’s operating losses, working capital, and investment in strategic growth initiatives. The Company has incurred significant losses and negative cash flows from operations since inception and expects to continue to incur losses and negative cash flows for the foreseeable future as the Company expands its penetration of the quantum computing application development market. In accordance with Accounting Standards Codification (“ASC”) 205-40, <i>Going Concern</i>, the Company’s management has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">In April 2026, the Company sold and issued to accredited investors a total of <span id="xdx_901_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z2zqkZ6duC1j" title="Number of shares sold">15,000</span> shares of Series D preferred stock (which are convertible into <span id="xdx_908_eus-gaap--ProceedsFromConvertibleDebt_pn3n3_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_ziqyNKguY8Ve" title="Proceeds from issuance of convertible notes">34,160,784</span> shares of Common Stock, subject to adjustment) and Warrants to purchase up to <span id="xdx_907_ecustom--NumberOfWarrantPurchase_pid_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_znJSm83DFHea" title="Number of warrant purchase">17,080,392</span> shares of Common Stock (representing 50% warrant coverage on an as-converted basis) for total gross proceeds of $<span id="xdx_900_ecustom--GrossProceeds_pn3n3_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zALIo8PKtkWc" title="Gross proceeds">15,000</span>. The Company received net proceeds of $<span id="xdx_90B_ecustom--NetProceeds_pn3n3_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zNqElZSzXtk6" title="Net proceeds">13,838</span> after deducting commissions and fees (see Note 12). The Company intends to use the net proceeds for working capital and general corporate purposes. As of the issuance date of these financial statements, management now expects that the Company’s existing cash will be sufficient to fund the Company’s current operating plan for at least twelve months from the date of issuance of these financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">The Company is subject to risks and uncertainties similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, dependence on key individuals, risks associated with changes in information technology, and the ability to raise additional capital to fund operations. The Company’s long-term success is dependent upon its ability to successfully market, deliver, and scale its quantum computing application development solutions, increase revenue, meet its obligations, obtain additional capital when needed and, ultimately, achieve profitable operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Although Management believes that it will be able to continue to raise funds by sale of its securities to provide the additional cash needed to meet the Company’s obligations, the restructuring activities aimed at restarting certain aspects of its core business require substantial funds to implement and there is no assurance that the Company will be able to continue raising the additional capital necessary to continue operations and execute on the Company’s business plan.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> -1310000 999000 -9357000 642000 15000 34160784000 17080392 15000000 13838000 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zFzRDHdAL4L9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>2. <span id="xdx_827_z4z0qRQbc3M">Summary of Significant Accounting Policies </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company’s significant accounting policies are detailed in “Note 2. Summary of Significant Accounting Policies” of the Company’s Annual Report. The Company uses the same accounting policies in preparing its quarterly and annual consolidated financial statements. There have been no material changes to significant accounting policies during the three months ended March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_84F_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zDagNI25sD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z63T69UWssFl">Use of Estimates</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.7pt"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="font-size: 10pt">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to, revenue recognition, , the valuation of the Company’s Common Stock, and the fair value of stock-based awards. The Company’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions that the Company believes are reasonable under the circumstances. Actual results may differ materially from those estimates or assumptions.</span><span style="font-size: 4pt"> </span></p> <p id="xdx_848_ecustom--WarrantsIssuancePolicyTextBlock_z2Q4aBG2x3W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_868_zwiVyby4Qlmc">Warrant Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own Common Stock and whether the instrument holders could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding.</p> <p id="xdx_842_ecustom--OtherPoliciesPolicyTextBlock_zM0NvKHScRUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_z8Kc8Fb5yYUf">Other policies</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company’s other significant accounting policies are detailed in “Note 2. Summary of Significant Accounting Policies” of the Company’s Annual Report. The Company uses the same accounting policies in preparing its quarterly and annual consolidated financial statements. There have been no material changes to significant accounting policies during the three months ended March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXmQ7AXpalHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_zPk2RDeJGuag">Recently Issued Accounting Pronouncements </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)</i>: <i>Disaggregation of Income Statement Expenses</i>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Other recent accounting pronouncements and guidance issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p> <p id="xdx_84F_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zDagNI25sD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_860_z63T69UWssFl">Use of Estimates</span> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27.7pt"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="font-size: 10pt">The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to, revenue recognition, , the valuation of the Company’s Common Stock, and the fair value of stock-based awards. The Company’s estimates are based on historical information available as of the date of the unaudited condensed consolidated financial statements and various other assumptions that the Company believes are reasonable under the circumstances. Actual results may differ materially from those estimates or assumptions.</span><span style="font-size: 4pt"> </span></p> <p id="xdx_848_ecustom--WarrantsIssuancePolicyTextBlock_z2Q4aBG2x3W2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_868_zwiVyby4Qlmc">Warrant Instruments</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815. The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own Common Stock and whether the instrument holders could potentially require net cash settlement in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and, for liability-classified warrants, at each reporting period end date while the warrants are outstanding.</p> <p id="xdx_842_ecustom--OtherPoliciesPolicyTextBlock_zM0NvKHScRUk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_867_z8Kc8Fb5yYUf">Other policies</span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company’s other significant accounting policies are detailed in “Note 2. Summary of Significant Accounting Policies” of the Company’s Annual Report. The Company uses the same accounting policies in preparing its quarterly and annual consolidated financial statements. There have been no material changes to significant accounting policies during the three months ended March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p id="xdx_848_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zXmQ7AXpalHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i><span id="xdx_86B_zPk2RDeJGuag">Recently Issued Accounting Pronouncements </span></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">In November 2024, the FASB issued ASU 2024-03, <i>Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40)</i>: <i>Disaggregation of Income Statement Expenses</i>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently in the process of evaluating the impact of this pronouncement on its related disclosures.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Other recent accounting pronouncements and guidance issued by the FASB, its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p> <p id="xdx_808_ecustom--DisclosureOfAccruedExpensesAndOtherCurrentLiabilitiesTextBlock_z6lbmLUf7C09" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>3. <span id="xdx_82A_zGKPuOjqTwsa">Accrued Expenses and Other Current Liabilities </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Accrued expenses and other current liabilities consisted of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_pn3n3_zXxVEIiCq2d9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BF_zxYUyysS8Nxd" style="display: none"> Schedule of accrued expenses and other current liabilities</td><td> </td> <td colspan="2" id="xdx_492_20260331_zMB8tLEjGBRl"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20251231_z6MB4iKH0NK4"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31,<br/> 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALAOLzGVG_ztfDyAXVx0Fl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Accrued employee compensation and benefit</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">7</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">73</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALAOLzGVG_zoNPE4LzHHa4" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Accrued professional fees</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">331</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">259</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALAOLzGVG_zGdGyZ4fbnV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Refunds payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">750</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">750</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALAOLzGVG_zkRBkwvjRJd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">459</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">682</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtALAOLzGVG_zk1qKy0CHbf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; color: rgb(204,238,255); text-align: left; padding-bottom: 2.5pt">Accrued expenses and other current liabilities</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,547</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,764</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--SummaryOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_pn3n3_zXxVEIiCq2d9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Accrued Expenses and Other Current Liabilities (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BF_zxYUyysS8Nxd" style="display: none"> Schedule of accrued expenses and other current liabilities</td><td> </td> <td colspan="2" id="xdx_492_20260331_zMB8tLEjGBRl"> </td><td> </td><td> </td> <td colspan="2" id="xdx_495_20251231_z6MB4iKH0NK4"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31,<br/> 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--AccruedEmployeeBenefitsCurrent_iI_pn3n3_maALAOLzGVG_ztfDyAXVx0Fl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Accrued employee compensation and benefit</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">7</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">73</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--AccruedProfessionalFeesCurrent_iI_pn3n3_maALAOLzGVG_zoNPE4LzHHa4" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Accrued professional fees</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">331</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">259</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--InterestPayableCurrent_iI_pn3n3_maALAOLzGVG_zGdGyZ4fbnV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Refunds payable</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">750</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">750</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pn3n3_maALAOLzGVG_zkRBkwvjRJd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt">Other</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">459</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">682</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesAndOtherLiabilities_iTI_pn3n3_mtALAOLzGVG_zk1qKy0CHbf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; color: rgb(204,238,255); text-align: left; padding-bottom: 2.5pt">Accrued expenses and other current liabilities</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,547</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,764</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 7000 73000 331000 259000 750000 750000 459000 682000 1547000 1764000 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zzhK3vvTJMN9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>4. <span id="xdx_82B_zQRqkPt44fWc">Debt </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">The aggregate principal amount of debt outstanding as of March 31, 2026 and December 31, 2025 consisted of the following:</p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDebtTableTextBlock_pn3n3_zIju2xLiNund" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BD_zJdxCUDl9r1k" style="display: none"> Schedule of the aggregate principal amount of debt outstanding</td><td> </td> <td colspan="2" id="xdx_498_20260331_zp9qYPIDuvH9"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20251231_z1cCnN0VyGv"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31,<br/> 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_404_ecustom--SeniorSecuredNotes_iI_pn3n3_maDLASCzNiz_z0J07vVNmdJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Senior secured notes</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,311</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,273</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ConvertiblePromissoryNotesNoncurrent_iI_pn3n3_maDLASCzNiz_zIPPr2Y6K0Jg" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible promissory notes</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,227</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,133</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iTI_pn3n3_mtDLASCzNiz_zx1z3She9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; color: rgb(204,238,255); text-align: left; padding-bottom: 2.5pt">Total Debt</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,538</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,406</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Senior Secured Notes </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">The Senior Secured Notes bear interest at the compound rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_c20260101__20260331__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_z2QIW4FgnUe4" title="Interest rate">15%</span> per annum and are convertible at the option of each noteholder at $<span id="xdx_90C_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zYZhzNTUbLg9" title="Share price">8.50 </span>per share. The outstanding principal amount of the Senior Secured Notes and all accrued but unpaid interest will be due and payable at the maturity date, <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_c20260101__20260331__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_z7QQ8CjITkT3" title="Maturity date">December 15, 2026</span>, unless otherwise converted. While any Senior Secured Notes are outstanding, the Company cannot incur additional indebtedness for borrowed funds, except additional Senior Secured Notes, substantially similar notes or other debt instruments that are pari passu with or subordinate to the Senior Secured Notes.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">As of December 31, 2025, the aggregate principal and accrued interest outstanding under the Senior Secured Notes totaled $<span id="xdx_90A_eus-gaap--SecuredDebt_iI_pn3n3_c20251231__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zk1gHfRkVYM5" title="Secured debt">1,273</span>. The Company recognized approximately $<span id="xdx_904_eus-gaap--InterestExpense_pn3n3_c20260101__20260331__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zrRsATbLp6O6" title="Interest expense">38</span> of interest expense for the three months ended March 31, 2026, which is included within interest expense in the condensed consolidated statements of operations and comprehensive income (loss). As of March 31, 2026, the aggregate principal and accrued interest outstanding under the Senior Secured Notes totaled $<span id="xdx_908_eus-gaap--SecuredDebt_iI_pn3n3_c20260331__us-gaap--LongtermDebtTypeAxis__custom--SeniorSecuredNotesMember_zfAOTrNJV0zf" title="Secured debt">1,311</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Convertible Promissory Notes</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">In June 2025 the Company entered into a security purchase agreement with accredited investors pursuant to which the Company sold and issued secured convertible promissory notes (“Convertible Promissory Notes”) and warrants to purchase <span id="xdx_904_ecustom--NumberOfWarrantPurchase_pid_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zdAdegoA3bTe" title="Number of warrant purchase">37,500,000</span> shares of Common Stock (“Warrants”) for total gross proceeds of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfWarrants_pn3n3_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zVEiK01xLHPl" title="Proceeds from warrant">3,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"><span style="font-size: 10pt">The Convertible Promissory Notes bear simple interest at a rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember__srt--CounterpartyNameAxis__custom--AccreditedInvestorsMember_zXw4Ys2XAp8j" title="Interest rate">10.00%</span> per annum and mature in June 2026, unless earlier converted or repaid in accordance with its terms. Interest accrues daily based on a 360-day year and will not be paid in cash prior to maturity unless the Convertible Promissory Notes are repaid before conversion.</span></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Convertible Promissory Notes may not be prepaid before the maturity date without the written consent of the holder and is secured pursuant to a Security Agreement entered into concurrently with the issuance.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Convertible Promissory Notes are convertible into <span id="xdx_90E_eus-gaap--ConversionOfStockSharesConverted1_pid_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zAAt83r7Q7i6" title="Number of conversion share converted">75,000,000</span> shares of the Company’s Common Stock at the option of the holder at any time prior to repayment. The conversion price is $<span id="xdx_904_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_pid_c20250630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zM8Ff5YWpeol" title="Conversion price">0.04 </span>per share, subject to customary anti-dilution adjustments for stock splits, stock dividends, combinations, or recapitalizations (the “Conversion Price”). Upon conversion, any unpaid accrued interest is automatically forgiven.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The outstanding principal balance under the Convertible Promissory Notes automatically convert into Common Stock upon the closing of a Qualified Financing, which excludes the issuance of Preferred Shares, with aggregate gross proceeds of at least $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pn3n3_c20250601__20250630__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zWiXPFb6nIO2" title="Proceeds from conversion amount converted">5,000</span>, at the Conversion Price. In the event of a Change of Control prior to maturity, the holder may elect to (i) have the outstanding principal and accrued interest repaid in full or (ii) convert the principal into shares of Common Stock at the Conversion Price. Accrued interest is forgiven upon such conversion.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Upon the occurrence of an Event of Default and written notice from the holder (or automatically upon certain bankruptcy-related events), the Convertible Promissory Notes become immediately due and payable, together with all accrued interest. Events of Default include (i) failure to pay principal or interest when due, (ii) breaches of covenants in the Convertible Promissory Notes or the Securities Purchase Agreement, (iii) bankruptcy or insolvency events, and (iv) defaults under other indebtedness exceeding $200.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">In connection with the issuance of the Convertible Promissory Notes, the Company incurred debt issuance costs totaling $<span id="xdx_90A_eus-gaap--DeferredFinanceCostsNet_iI_pn3n3_c20260331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zuIXqV9HN783" title="Debt issuance costs">75</span>. These costs were recorded as a reduction to the carrying value of the Convertible Promissory Notes and are amortized to interest expense over the one-year term using the effective interest method. The effective interest rate on the Convertible Note is <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_c20260331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zvG1jSzIHeoe" title="Effective interest rate">12.64%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> The Company accounts for its Convertible Promissory Notes at amortized cost. No portion of the proceeds was allocated to the conversion features, as the embedded conversion options did not require separate derivative accounting and the notes were not issued at a premium subject to ASC 470. The fair value of the warrants issued in connection with the notes was not material.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">The balance of the Convertible Promissory Notes and accrued interest was $<span id="xdx_90A_ecustom--AccruedInterest_pn3n3_c20240101__20241231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zUr9tBAgXjS3" title="Accrued interest">3,113</span> at December 31, 2025. The Company recognized approximately $<span id="xdx_904_eus-gaap--InterestExpense_pn3n3_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zhvae0NDKvAj" title="Interest expense">75</span> of interest expense for the three months ended March 31, 2026, which is included within interest expense in the condensed consolidated statements of operations and comprehensive income (loss). Interest expense attributable to the amortization of debt issuance costs incurred with third-party financing arrangements was $<span id="xdx_902_eus-gaap--AmortizationOfDebtDiscountPremium_pn3n3_c20260101__20260331__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zitJtcjsBoY" title="Amortization of debt issuance costs">19</span> and recorded to interest expense for the three months ended March 31, 2026. The balance of the Convertible Promissory Notes and accrued interest was $<span id="xdx_903_ecustom--AccruedInterest_pn3n3_c20250101__20251231__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementMember__us-gaap--LongtermDebtTypeAxis__custom--ConvertiblePromissoryNotesMember_zyEfgIsHTFre" title="Accrued interest">3,227</span> at March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">  </p> <table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleOfDebtTableTextBlock_pn3n3_zIju2xLiNund" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Debt (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BD_zJdxCUDl9r1k" style="display: none"> Schedule of the aggregate principal amount of debt outstanding</td><td> </td> <td colspan="2" id="xdx_498_20260331_zp9qYPIDuvH9"> </td><td> </td><td> </td> <td colspan="2" id="xdx_496_20251231_z1cCnN0VyGv"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31,<br/> 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">December 31,<br/> 2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_404_ecustom--SeniorSecuredNotes_iI_pn3n3_maDLASCzNiz_z0J07vVNmdJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Senior secured notes</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,311</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right">1,273</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--ConvertiblePromissoryNotesNoncurrent_iI_pn3n3_maDLASCzNiz_zIPPr2Y6K0Jg" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">Convertible promissory notes</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,227</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,133</td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DebtLongtermAndShorttermCombinedAmount_iTI_pn3n3_mtDLASCzNiz_zx1z3She9we3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; color: rgb(204,238,255); text-align: left; padding-bottom: 2.5pt">Total Debt</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,538</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4,406</td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 1311000 1273000 3227000 3133000 4538000 4406000 0.15 8.50 2026-12-15 1273000 38000 1311000 37500000 3000000 0.1000 75000000 0.04 5000000 75000 0.1264 3113000 75000 19000 3227000 <p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zug03FZ57G4b" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>5. <span id="xdx_82C_zDRUEhYdCcFe">Commitment and Contingencies</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Forbearance Agreements</i></b></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">During the year ended December 31, 2025, the <span id="xdx_903_ecustom--ForbearanceAgreementDescription_c20250101__20251231__custom--AgreementAxis__custom--ForbearanceAgreementsMember_zH5mIAR7HHOi" title="Forbearance agreement description">Company entered into forbearance agreements (the “Forbearance Agreement”) with two third-party creditors related to outstanding invoices totaling approximately $3,774 (the “Overdue Amount”). Pursuant to the Forbearance Agreement, 50% of the Overdue Amount (approximately $<span id="xdx_904_eus-gaap--ExtinguishmentOfDebtAmount_pn3n3_c20250101__20251231__custom--AgreementAxis__custom--ForbearanceAgreementsMember_zId1EKuW1CZ5" title="Extinguishment of debt">1,887</span>), remains due, and the remaining $1,887 becomes contingently payable based upon the completion of capital-raising transactions generating at least $45,000 and $55,000, respectively, in aggregate proceeds  .</span> If the specified financing thresholds are not achieved, the corresponding contingent payments will not become due, and the related obligations will be permanently extinguished.  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">Pursuant to the Forbearance Agreement, the creditors have each agreed to temporarily forbear from enforcing collection of the $1,887, that is currently recorded in accounts payable during the forbearance period, and, in either case, if the specified financing thresholds are not achieved, the corresponding contingent payments will not become due, and the related obligations will be permanently extinguished.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">During the year ended December 31, 2025, the Company accounted for the $1,887 Overdue Amount that is now contingently payable as an extinguishment of debt due to management’s assessment that it is not probable that the Company reach the equity raising threshold that would require repayment of these amounts.<br/>  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Beginning May 1, 2025, any unpaid portion of the Obligations will accrue a late charge at a rate equal to the lesser of 0.8% per month or the maximum rate permitted by law. The forbearance period will terminate—and the Remaining Overdue Amount, together with any accrued late charges, will become immediately due and payable—upon the occurrence of certain “Forbearance Termination Events,” including specified capital-raising or asset-sale transactions, defaults, or insolvency events. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> Company entered into forbearance agreements (the “Forbearance Agreement”) with two third-party creditors related to outstanding invoices totaling approximately $3,774 (the “Overdue Amount”). Pursuant to the Forbearance Agreement, 50% of the Overdue Amount (approximately $1,887), remains due, and the remaining $1,887 becomes contingently payable based upon the completion of capital-raising transactions generating at least $45,000 and $55,000, respectively, in aggregate proceeds  . 1887000 <p id="xdx_80E_ecustom--TemporaryEquityTextBlock_zoIxFtp21jdj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. <span id="xdx_82F_zfb4bs5zFEfg">Convertible Preferred Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Series A Convertible Preferred Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">As of March 31, 2026, the authorized, issued, and outstanding Series A Convertible Preferred Stock and their principal were as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ConvertiblePreferredStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3mDfzyza9zb" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Preferred Stock (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BA_zWlnIy30bs58" style="display: none; text-align: center"> Summary of convertible preferred stock</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="18" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Par Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock Issued<br/> and Outstanding</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Liquidation<br/> Preference</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Common Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Series A Preferred Stock</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0GWfuF8j3kb" title="Par Value">0.0001</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkbV4g4rkXH8" title="Preferred Stock Authorized">15,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKAMthEQJOlg" title="Preferred Stock Issued and Outstanding">15,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zH2p5rnUMAe2" title="Carrying Value">1,500</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIdQesYVtar1" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0484">—</span></span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zM21zSsooNIj" title="Common Stock Issuable Upon Conversion">15,000,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zL7UnjoykHdc" title="Preferred Stock Authorized">15,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z15oUAFjUMX8" title="Preferred Stock Issued and Outstanding">15,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrdnxFVPollk" title="Carrying Value">1,500</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUhQelKYiOQh" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0494">—</span></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdiqrgHu7ocl" title="Common Stock Issuable Upon Conversion">15,000,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AE_zsMbnxYVSHkc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">Each share of Series A is convertible into <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zMCLNMvGod4e" title="Number of conversion share converted">1,000</span> shares of Common Stock of the Company at the election of the holder, subject to certain adjustments and to beneficial ownership limitations. Each share of Series A shall be entitled to vote with the Company’s Common Stock on an as-converted basis, subject to beneficial ownership limitations. All shares of capital stock of the Company, both Common Stock and any other series of preferred stock, shall be junior in rank to all shares of Series A with respect to payments upon the liquidation, dissolution, and winding up of the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Series C Convertible Preferred Stock</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">As of March 31, 2026, the authorized, issued, and outstanding Series C Convertible Preferred Stock and their principal were as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ConvertiblePreferredStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zucY3zoCYeX7" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Preferred Stock (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8B0_zMuXtRmO5Pf8" style="display: none"> Summary of convertible preferred stock</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="18" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Par Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock Issued<br/> and Outstanding</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Liquidation<br/> Preference</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Common Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Series C Preferred Stock</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pd" title="Par Value">0.0001</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYhfXtjjhBnl" title="Preferred Stock Authorized">23,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq0SJUM2MPxj" title="Preferred Stock Issued and Outstanding">11,983</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zW5WOHSclJah" title="Carrying Value">4,429</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zu8sOv7DkTah" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0510">—</span></span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zaLiXHU5QAlk" title="Common Stock Issuable Upon Conversion">11,983,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zFqT5w41hi4e" title="Preferred Stock Authorized">23,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zem5lhqNWth1" title="Preferred Stock Issued and Outstanding">11,983</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zQookGcsG5cd" title="Carrying Value">4,429</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAVKR12Kisa1" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0520">—</span></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq0jJMZoVHCj" title="Common Stock Issuable Upon Conversion">11,983,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8AF_zC9gvPW8coLb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Each share of Series C Convertible Preferred Stock is convertible into <span id="xdx_909_eus-gaap--ConversionOfStockSharesConverted1_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_z5VudV8Wi15f" title="Number of conversion share converted">1,000</span> shares of Common Stock of the Company at the election of the holder, subject to certain adjustments and to beneficial ownership limitations. Each share of Series C Convertible Preferred Stock shall be entitled to vote with the Company’s Common Stock on an as-converted basis, subject to beneficial ownership limitations. The holders of Series C Convertible Preferred Stock shall rank pari passu with the holders of Common Stock with respect to any liquidation, dissolution or winding up of the Company. The Series C Convertible Preferred Stock are not redeemable.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_899_ecustom--ConvertiblePreferredStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_z3mDfzyza9zb" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Preferred Stock (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BA_zWlnIy30bs58" style="display: none; text-align: center"> Summary of convertible preferred stock</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="18" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Par Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock Issued<br/> and Outstanding</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Liquidation<br/> Preference</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Common Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Series A Preferred Stock</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z0GWfuF8j3kb" title="Par Value">0.0001</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zkbV4g4rkXH8" title="Preferred Stock Authorized">15,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_904_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKAMthEQJOlg" title="Preferred Stock Issued and Outstanding">15,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zH2p5rnUMAe2" title="Carrying Value">1,500</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zIdQesYVtar1" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0484">—</span></span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_908_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zM21zSsooNIj" title="Common Stock Issuable Upon Conversion">15,000,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zL7UnjoykHdc" title="Preferred Stock Authorized">15,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_z15oUAFjUMX8" title="Preferred Stock Issued and Outstanding">15,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrdnxFVPollk" title="Carrying Value">1,500</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zUhQelKYiOQh" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0494">—</span></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90B_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zdiqrgHu7ocl" title="Common Stock Issuable Upon Conversion">15,000,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 0.0001 15000 15000 1500000 15000000 15000 15000 1500000 15000000 1000 <table cellpadding="0" cellspacing="0" id="xdx_896_ecustom--ConvertiblePreferredStockTableTextBlock_hus-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zucY3zoCYeX7" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Convertible Preferred Stock (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8B0_zMuXtRmO5Pf8" style="display: none"> Summary of convertible preferred stock</td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="18" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1pt"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="18" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Par Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock<br/> Authorized</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Preferred<br/> Stock Issued<br/> and Outstanding</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Carrying<br/> Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Liquidation<br/> Preference</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Common Stock<br/> Issuable Upon<br/> Conversion</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 22%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Series C Preferred Stock</td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_pd" title="Par Value">0.0001</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zYhfXtjjhBnl" title="Preferred Stock Authorized">23,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq0SJUM2MPxj" title="Preferred Stock Issued and Outstanding">11,983</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zW5WOHSclJah" title="Carrying Value">4,429</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zu8sOv7DkTah" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0510">—</span></span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; width: 10%; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zaLiXHU5QAlk" title="Common Stock Issuable Upon Conversion">11,983,000</span></td><td style="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"> </td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zFqT5w41hi4e" title="Preferred Stock Authorized">23,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90D_ecustom--PreferredStockIssuedAndOutstanding_iI_pid_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zem5lhqNWth1" title="Preferred Stock Issued and Outstanding">11,983</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--PreferredStockValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zQookGcsG5cd" title="Carrying Value">4,429</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--PreferredStockLiquidationPreferenceValue_iI_pn3n3_c20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zAVKR12Kisa1" title="Liquidation Preference"><span style="-sec-ix-hidden: xdx2ixbrl0520">—</span></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_ecustom--CommonStockIssuableUponConversion_pid_c20260101__20260331__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesCPreferredStockMember_zq0jJMZoVHCj" title="Common Stock Issuable Upon Conversion">11,983,000</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 0.0001 23000 11983 4429000 11983000 23000 11983 4429000 11983000 1000 <p id="xdx_800_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z5Ceo0XdCp7d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. <span id="xdx_822_zSRcbj9B8OS">Common Stock</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">As of March 31, 2026 and December 31, 2025, the Company had authorized <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20260331_pd" title="Common stock authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20251231_pd" title="Common stock authorized">600,000,000</span></span> shares of $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20260331_pd" title="Par value of common stock"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20251231_pd" title="Par value of common stock">0.0001</span></span> par value Common Stock. Each share of Common Stock entitles the holder to one vote, together with the holders of the Series A and Series C Convertible Preferred Stock (on an as-converted basis), on all matters submitted to the stockholders for a vote. The holders of Common Stock are entitled to receive dividends, if any, as declared by the Company’s Board of Directors.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Under the terms of the Company’s certificate of incorporation, the Company’s Board of Directors is authorized to direct the Company, without any action or vote by its stockholders (except as may be provided by the terms of any class or series of Company preferred stock then outstanding), to issue shares of preferred stock in one or more series without the approval of the Company’s stockholders. The Company’s Board of Directors has the discretion to determine the rights, powers, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><span style="text-decoration: underline">2025 Activity</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Restricted Stock Units</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">A total of <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c20250101__20250331_pd" title="Restricted stock units vested">25,000</span> restricted stock units vested during the three months ended March 31, 2025, and the corresponding shares were issued upon vesting.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i></i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unvested Shares </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 11pt 0pt 0; text-indent: 21.4pt">In connection with the closing on March 28, 2024 of the business combination with Andretti Acquisition Corp. (“AAC”), <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_pid_c20240326__20240328_zGuyB4oV285a" title="Number of shares unvested and forfeiture">1,129,630</span> shares of Sponsor Shares became unvested and are subject to the forfeiture pursuant to the available cash provisions as described in the sponsor support agreement in contemplation of the Merger. All of the Unvested Shares will become vested if, within three <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20240326__20240328_zPdMIAGDR38b" style="display: none" title="Weighted average remaining contractual term">3</span> years of the closing, the volume-weighted average price of the Company’s Common Stock equals or exceeds $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20240328_zaHq2Dx5mm3i" title="Share price">12.00</span> per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations) for any <span id="xdx_900_ecustom--AggregateNumberOfTradingDaysForDeterminingSharePrice_dtD_c20240326__20240328_z4VdOvCP9y28" title="Aggregate number of trading days for determining the share price">20</span> trading days within any <span id="xdx_907_ecustom--NumberOfConsecutiveTradingDaysForDeterminingSharePrice_dtD_c20240326__20240328_z6R2W3FBAAV2" title="Number of consecutive trading days for determining the share price">30</span>-trading day period, or if there is a change of control of the Company. If neither of these events occur within three <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20240326__20240328_zGBT11XDs9y9" style="display: none" title="Award vesting period">3</span> years of the closing, then the Unvested Shares will be forfeited and shall be transferred by the sponsor and the sponsor co-investor to the Company, without any consideration for such transfer. The Unvested Shares are indexed to the Company’s own stock and are therefore classified as equity in the Company’s consolidated financial statements. <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_pid_do_c20260331_z1uXsyaQRgr7" title="Number of unvested shares">No</span> Unvested Shares vested during the three months ended March 31, 2026 or 2025.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> 600000000 600000000 0.0001 0.0001 25000 1129630 P3Y 12.00 P20D P30D P3Y 0 <p id="xdx_802_eus-gaap--ProductWarrantyDisclosureTextBlock_za86xgGoLw9a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. <span id="xdx_829_z49n5BMaAWli">Warrants </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Public Warrants and Private Placement Warrants</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><i> </i> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Public Warrants and Private Placement Warrants are exercisable to purchase one share of the Company’s Common Stock at $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJvL8WKYv5pe" title="Class of warrants or rights exercise price per share"><span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCtKaVgyuZ61" title="Class of warrants or rights exercise price per share">11.50 </span></span>per share. Public Warrants may be redeemed, in whole and not in part, at $0.01 per warrant with <span id="xdx_901_ecustom--ClassOfWarrantsOrRightsMinimumNoticePeriodToBeGivenToWarrantHoldersBeforeRedemption_dtD_c20260101__20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zr7kPB6O7SWa" title="Class of warrants or rights minimum notice period to be given to warrant holders before redemption">30</span> days’ notice if the Company’s Common Stock trades at or above $<span id="xdx_906_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJt6p29D2i3j" title="Share price">18.00 </span>for <span id="xdx_90A_ecustom--AggregateNumberOfTradingDaysForDeterminingSharePrice_dtD_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zOpqYAxvpmb4" title="Aggregate number of trading days for determining the share price">20</span> trading days out of <span id="xdx_90E_ecustom--NumberOfConsecutiveTradingDaysForDeterminingSharePrice_dtD_c20260101__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zA2MAWQjHbjj" title="Number of consecutive trading days for determining the share price">30</span> trading days. The Company may require holders to exercise Public Warrants on a cashless basis if the warrants are called for redemption. Private Placement Warrants are substantially identical to the Public Warrants except that (i) they cannot be redeemed by the Company, (ii) they are permanently exercisable on a cashless basis, and (iii) they are not transferable, assignable, or salable until 30 days after the closing date, except to permitted transferees. Private Placement Warrants also provide for an alternative issuance in the event of a tender offer or other change-of-control transaction, consistent with the warrant agreement.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">The Warrants expire on the fifth anniversary of the Merger or earlier upon redemption or liquidation and are exercisable commencing 30 days after the Merger, provided that the Company has an effective registration statement under the Securities Act covering the shares of the Company’s Common Stock issuable upon exercise of the Warrants and a current prospectus relating to them is available or a valid exemption is available.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">As of March 31, 2026 and December 31, 2025, there were <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zxuQe50UbQg8" title="Class of warrant or right, outstanding">11,499,982</span> and <span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PublicWarrantsMember_zL2Mdqnszzq" title="Class of warrant or right, outstanding">11,499,982</span> Public Warrants outstanding, respectively. As of March 31, 2026 and December 31, 2025, there were <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20260331__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_zYg5gTAumVVj" title="Class of warrant or right, outstanding">55,800,000</span> and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20251231__us-gaap--ClassOfWarrantOrRightAxis__custom--PrivatePlacementWarrantsMember_zAIM61K2vQa2" title="Class of warrant or right, outstanding">55,800,000</span> Private Placement Warrants outstanding, respectively. The Public Warrants and Private Placement Warrants qualify for equity classification in accordance with ASC 815-40, <i>Derivatives and Hedging</i>. Accordingly, the Warrants were initially measured at fair value and recorded within equity with no subsequent measures of changes in fair value.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 25.4pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 25.4pt">Warrant activity during the three months ended March 31, 2026 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--ScheduleOfWarrantyEffectReverseRecapitalizationTableTextBlock_pn3n3_zSpTHuP3s3xb" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BE_zpoqZrotRUB7" style="display: none">Schedule of effect of the reverse recapitalization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Balance at December 31, 2025</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUgSZzJXpHrd" title="Number of Shares, Beginning Balance">67,299,982</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEjD0cWVxw3i" title="Weighted- Average Exercise Price, Beginning Balance">4.31</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjBftn4WufGi" title="Weighted-Average Remaining Contractual Term (Years)">3.97</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xYC0Jq37e" title="Aggregate Intrinsic Value, Beginning Balance">65,096</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 13.5pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcvepZwTGcpi" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0585">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5o2Sb9bA2ec" title="Weighted- Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0587">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 13.5pt">Exercised</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN4rokQGRcsk" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0589">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyJuSZVhQpdi" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0591">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Forfeited and expired</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zgBxYOPUkCBj" title="Number of Shares, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0593">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDSuSjsRVMv6" title="Weighted- Average Exercise Price, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0595">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7BacctKH67j" title="Number of Shares, Ending Balance">67,299,982</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJnjqz52580j" title="Weighted- Average Exercise Price, Ending Balance">4.31</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxVCafDcUgL8" title="Weighted-Average Remaining Contractual Term (Years)">3.72</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlZP5etu8ROc" title="Aggregate Intrinsic Value, Ending Balance">17,745</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Warrants vested and exercisable at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3BsMsdCjSyb" title="Number of Shares, Options vested and exercisable">66,399,982</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyl5QoGqQBaf" title="Weighted- Average Exercise Price, Options vested and exercisable">4.31</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPI9Urj6wz7a" title="Weighted-Average Remaining Contractual Term (Years), Options vested and exercisable">3.72</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pn3n3_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWw9QQEyz5d" title="Aggregate Intrinsic Value, Options vested and exercisable">17,367</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="font: 12pt/115% Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 25.4pt">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on a fair market value of $<span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331__us-gaap--AwardTypeAxis__custom--WarrantsMember_z4bEaD11TkTi" title="Weighted-average grant-date fair value of warrants granted">0.42</span> per share on March 31, 2026, the intrinsic value attributed to exercisable and unexercised Common Stock warrants was $<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_c20260331__us-gaap--AwardTypeAxis__custom--WarrantsMember_zIKxmRd05Ny9" title="Intrinsic value attributed to exercisable and unexercised">17,367</span> at March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="letter-spacing: -0.05pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="letter-spacing: -0.05pt">As of March 31, 2026, there was <span id="xdx_908_ecustom--UnrecognizedCompensationCost_pn3n3_do_c20260101__20260331_zSwnggu9elEa" title="Unrecognized compensation cost">no</span> unrecognized compensation cost related</span> to unvested warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p> 11.50 11.50 P30D 18.00 P20D P30D 11499982 11499982 55800000 55800000 <table cellpadding="0" cellspacing="0" id="xdx_886_ecustom--ScheduleOfWarrantyEffectReverseRecapitalizationTableTextBlock_pn3n3_zSpTHuP3s3xb" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Warrants (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8BE_zpoqZrotRUB7" style="display: none">Schedule of effect of the reverse recapitalization</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Balance at December 31, 2025</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zUgSZzJXpHrd" title="Number of Shares, Beginning Balance">67,299,982</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zEjD0cWVxw3i" title="Weighted- Average Exercise Price, Beginning Balance">4.31</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zjBftn4WufGi" title="Weighted-Average Remaining Contractual Term (Years)">3.97</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z4xYC0Jq37e" title="Aggregate Intrinsic Value, Beginning Balance">65,096</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 13.5pt">Granted</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zcvepZwTGcpi" title="Number of Shares, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0585">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z5o2Sb9bA2ec" title="Weighted- Average Exercise Price, Granted"><span style="-sec-ix-hidden: xdx2ixbrl0587">—</span></span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 13.5pt">Exercised</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zN4rokQGRcsk" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0589">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyJuSZVhQpdi" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0591">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Forfeited and expired</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zgBxYOPUkCBj" title="Number of Shares, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0593">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zDSuSjsRVMv6" title="Weighted- Average Exercise Price, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0595">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z7BacctKH67j" title="Number of Shares, Ending Balance">67,299,982</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zJnjqz52580j" title="Weighted- Average Exercise Price, Ending Balance">4.31</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zxVCafDcUgL8" title="Weighted-Average Remaining Contractual Term (Years)">3.72</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zlZP5etu8ROc" title="Aggregate Intrinsic Value, Ending Balance">17,745</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Warrants vested and exercisable at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_z3BsMsdCjSyb" title="Number of Shares, Options vested and exercisable">66,399,982</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zyl5QoGqQBaf" title="Weighted- Average Exercise Price, Options vested and exercisable">4.31</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zPI9Urj6wz7a" title="Weighted-Average Remaining Contractual Term (Years), Options vested and exercisable">3.72</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pn3n3_c20260331__us-gaap--AwardTypeAxis__us-gaap--WarrantMember_zWWw9QQEyz5d" title="Aggregate Intrinsic Value, Options vested and exercisable">17,367</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 67299982 4.31 P3Y11M19D 65096000 67299982 4.31 P3Y8M19D 17745000 66399982 4.31 P3Y8M19D 17367000 0.42 17367000 0 <p id="xdx_809_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_z1AatkisfNoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. <span id="xdx_826_z342t91hyvbl">Compensation Plans</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Stock Option</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5pt 0pt 0; text-indent: 25.4pt">Stock option activity during the three months ended March 31, 2026 is as follows:</p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_pn3n3_zK8yNhrhJfI9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Compensation Plans (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B8_z8DIizvZmJpd" style="display: none"> Summary of assumptions used in Black-Scholes option-pricing model to determine fair value of stock options granted</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Balance at December 31, 2025</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQAXOseAkuza" title="Number of Shares, Beginning Balance">39,003,451</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUheVUsmHgNe" title="Weighted- Average Exercise Price, Beginning Balance">0.08</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLVh0ZO8dtT5" title="Weighted-Average Remaining Contractual Term (Years)">9.62</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzAGUM4xx6v9" title="Aggregate Intrinsic Value, Beginning Balance">58,598</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 13.5pt">Granted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQu4mG1TElK1" title="Number of Shares, Granted">650,000</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFBsMIhH0neh" title="Weighted- Average Exercise Price, Granted">0.92</span></td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 13.5pt">Exercised</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z15mNu8M9MCb" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0636">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2IKzMjiQ08j" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0638">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Forfeited and expired</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2PHjnKHI5J9" title="Weighted- Average Exercise Price, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0640">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYVx32ojlpCa" title="Weighted- Average Exercise Price, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0642">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXLOV3BJVgp3" title="Number of Shares, Ending Balance">39,653,451</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2dIO6ncNrH2" title="Weighted- Average Exercise Price, Ending Balance">0.09</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUY3berWJfN1" title="Weighted-Average Remaining Contractual Term (Years)">9.38</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRG9npIxnS8d" title="Aggregate Intrinsic Value, Ending Balance">13,031</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zmACP6aANfw4" title="Number of Shares, Options vested and exercisable">2,176,432</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztE5Y763GDe2" title="Weighted- Average Exercise Price, Options vested and exercisable">0.73</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6Dx0ViBQkhk" title="Weighted-Average Remaining Contractual Term (Years), Options vested and exercisable">8.24</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pn3n3_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9Slv3Wtvid1" title="Aggregate Intrinsic Value, Options vested and exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0658">—</span></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A4_zSHjrhfdTXuk" style="font: 12pt/115% Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-indent: 25.4pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">During the three months ended March 31, 2026, the Company granted options exercisable into <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhOrl7cMBYhc" title="Stock issued during period shares stock options exercised">650,000</span> shares of its Common Stock to its advisors. The stock options vest over a weighted average <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ziGtrnbmCoBi" title="Stock options vest">2.83</span> year period and are exercisable at a weighted average price of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKSWQn4GIPs9" title="Weighted average price exercisable">0.97</span> per share with an average life expiration of ten <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIizQ6Q8CaRe" style="display: none" title="Expiration">10</span> years. The total fair value of these options at the grant date was approximately $<span id="xdx_909_ecustom--FairValueOfStockGrant_pn3n3_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zr3FG0Hc3TVi" title="Fair value of stock grant">577,000</span>, which was determined using a Black-Scholes option pricing model with the following average assumption: stock price of $<span id="xdx_905_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1ckmqcnVMb1" title="Stock price">0.92</span> per share, expected term of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEQiLFBW2Ax7" title="Expected term">6.00</span> years, volatility of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pd" title="Volatility">150%</span>, dividend rate of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pd" title="Dividend rate">0%</span>, and weighted average risk-free interest rate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20260101__20260331__us-gaap--PlanNameAxis__custom--TwentyTwentyFourPlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pd" title="Risk-free interest rate">3.74%</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="letter-spacing: -0.05pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="letter-spacing: -0.05pt">As of March 31, 2026, there was $<span id="xdx_903_eus-gaap--DeferredCompensationArrangementWithIndividualAllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331_z5xp3As8GZli" title="Total unrecognized compensation cost related to unvested stock options">1,849</span> of total unrecognized compensation cost related</span> to unvested stock options. The Company expects to recognize the unrecognized compensation amount over a remaining weighted-average period of <span id="xdx_907_ecustom--UnrecognizedCompensationRemainingWeightedAveragePeriod_dtY_c20260101__20260331_zeHmhhWIPiTj" title="Unrecognized Compensation Remaining Weighted Average Period">3.26</span> years. The fair value of stock options that vested during the three months ended March 31, 2026 and 2025, was $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20260101__20260331_zWPzKCw2LAI2" title="Fair value of stock options vested">238 </span>and $<span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pn3n3_c20250101__20250331_zjSNtzRKV3d5" title="Fair value of stock options vested">44</span>, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Based on a fair market value of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_c20260101__20260331_z6fQIKIPyece" title="Weighted-average grant-date fair value of warrants granted">0.42 </span>per share on March 31, 2026, there was <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_pn3n3_do_c20260331_zldI29GoHeZ8" title="Intrinsic value attributed to exercisable and unexercised">no</span> intrinsic value attributed to exercisable and unexercised Common Stock options at March 31, 2026.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="letter-spacing: -0.05pt"> </span></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stock-Based Compensation</i></b></p> <p style="font: 10pt/120% Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="letter-spacing: -0.05pt">The following table below summarizes the classification of the Company’s stock-based compensation expense related to stock options and restricted</span> Common Stock in the consolidated statements of operations and comprehensive loss:</p> <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z3WDeHuvbn6k" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Compensation Plans (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B9_zJSnnqLhQQe2" style="display: none"> Summary of the classification of the company's stock-based compensation expense</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331__custom--IncomeStatementLocationsAxis__custom--ResearchAndDevelopmentExpensesMember_zEaJJIQUWnrk" title="Stock based compensation">87</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331__custom--IncomeStatementLocationsAxis__custom--ResearchAndDevelopmentExpensesMember_zRKMcEEBbh4d" title="Stock based compensation"><span style="-sec-ix-hidden: xdx2ixbrl0696">—</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Sales and marketing</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_zGorRRGEwD46" title="Stock based compensation">5</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right"><span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_znh707qOB59b" title="Stock based compensation"><span style="-sec-ix-hidden: xdx2ixbrl0700">—</span></span></td><td style="font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_zkQ3M06G982e" title="Stock based compensation">146</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_zeOAznrCQwM7" title="Stock based compensation">44</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331_zw5m4IHvNC37" title="Stock based compensation">238</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331_zGvRL9FT4nv7" title="Stock based compensation">44</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zzGqS16d1f1k" style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_pn3n3_zK8yNhrhJfI9" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Compensation Plans (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B8_z8DIizvZmJpd" style="display: none"> Summary of assumptions used in Black-Scholes option-pricing model to determine fair value of stock options granted</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise Price</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining<br/> Contractual Term<br/> (Years)</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Aggregate<br/> Intrinsic Value</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-size: 10pt">Balance at December 31, 2025</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQAXOseAkuza" title="Number of Shares, Beginning Balance">39,003,451</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUheVUsmHgNe" title="Weighted- Average Exercise Price, Beginning Balance">0.08</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zLVh0ZO8dtT5" title="Weighted-Average Remaining Contractual Term (Years)">9.62</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pn3n3_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zzAGUM4xx6v9" title="Aggregate Intrinsic Value, Beginning Balance">58,598</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 13.5pt">Granted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zQu4mG1TElK1" title="Number of Shares, Granted">650,000</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zFBsMIhH0neh" title="Weighted- Average Exercise Price, Granted">0.92</span></td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 13.5pt">Exercised</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z15mNu8M9MCb" title="Number of Shares, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0636">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2IKzMjiQ08j" title="Weighted- Average Exercise Price, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl0638">—</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 13.5pt">Forfeited and expired</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2PHjnKHI5J9" title="Weighted- Average Exercise Price, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0640">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zYVx32ojlpCa" title="Weighted- Average Exercise Price, Forfeited and expired"><span style="-sec-ix-hidden: xdx2ixbrl0642">—</span></span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt">Balance at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zXLOV3BJVgp3" title="Number of Shares, Ending Balance">39,653,451</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z2dIO6ncNrH2" title="Weighted- Average Exercise Price, Ending Balance">0.09</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zUY3berWJfN1" title="Weighted-Average Remaining Contractual Term (Years)">9.38</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pn3n3_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zRG9npIxnS8d" title="Aggregate Intrinsic Value, Ending Balance">13,031</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Options vested and exercisable at March 31, 2026</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zmACP6aANfw4" title="Number of Shares, Options vested and exercisable">2,176,432</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iI_pid_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_ztE5Y763GDe2" title="Weighted- Average Exercise Price, Options vested and exercisable">0.73</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z6Dx0ViBQkhk" title="Weighted-Average Remaining Contractual Term (Years), Options vested and exercisable">8.24</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iI_pn3n3_c20260331__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_z9Slv3Wtvid1" title="Aggregate Intrinsic Value, Options vested and exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0658">—</span></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 39003451 0.08 P9Y7M13D 58598000 650000 0.92 39653451 0.09 P9Y4M17D 13031000 2176432 0.73 P8Y2M26D 650000 P2Y9M29D 0.97 P10Y 577000000 0.92 P6Y 1.50 0 0.0374 1849000 P3Y3M3D 238000 44000 0.42 0 <table cellpadding="0" cellspacing="0" id="xdx_892_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_z3WDeHuvbn6k" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Compensation Plans (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B9_zJSnnqLhQQe2" style="display: none"> Summary of the classification of the company's stock-based compensation expense</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left">Research and development</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331__custom--IncomeStatementLocationsAxis__custom--ResearchAndDevelopmentExpensesMember_zEaJJIQUWnrk" title="Stock based compensation">87</span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 14%; font-size: 10pt; text-align: right"><span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331__custom--IncomeStatementLocationsAxis__custom--ResearchAndDevelopmentExpensesMember_zRKMcEEBbh4d" title="Stock based compensation"><span style="-sec-ix-hidden: xdx2ixbrl0696">—</span></span></td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Sales and marketing</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_zGorRRGEwD46" title="Stock based compensation">5</span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right"><span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331__custom--IncomeStatementLocationsAxis__custom--SellingAndMarketingExpensesMember_znh707qOB59b" title="Stock based compensation"><span style="-sec-ix-hidden: xdx2ixbrl0700">—</span></span></td><td style="font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_90A_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_zkQ3M06G982e" title="Stock based compensation">146</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331__custom--IncomeStatementLocationsAxis__custom--GeneralAndAdministrativeExpensesMember_zeOAznrCQwM7" title="Stock based compensation">44</span></td><td style="padding-bottom: 1pt; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_908_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20260101__20260331_zw5m4IHvNC37" title="Stock based compensation">238</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20250101__20250331_zGvRL9FT4nv7" title="Stock based compensation">44</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"> </td></tr> </table> 87000 5000 146000 44000 238000 44000 <p id="xdx_805_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zctxXiwQpmvl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. <span id="xdx_82F_z79Ipk4QKtAi">Segment Information</span></b></p> <p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27pt">The Company operates and manages its business activities on a consolidated basis and operates in a single reportable and operating segment. The Company’s Chief Executive Officer, serving as the Chief Operating Decision Maker (“CODM”), oversees operations on an aggregated basis to allocate resources effectively. In assessing the Company’s financial performance, the CODM regularly reviews consolidated net income (loss). Significant expense categories are not presented, as the expense information regularly provided to the CODM is presented on the same basis as the condensed consolidated statements of operations and comprehensive loss. The CODM relies on consolidated net loss as a comprehensive measure of the Company, considering all revenues and expenses, including cost of revenue, research and development expenses, general and administrative expenses and sales and marketing expenses, to assess the Company’s overall performance and inform strategic decisions on cost control, pricing and investments. Additionally, the CODM also reviews total assets to assess the Company's financial position and resource allocation. The measure of segment assets is reported on the condensed consolidated balance sheet as total consolidated assets. The Company’s long-lived assets consist primarily of property and equipment, net. As of March 31, 2026 the Company does not have material long-term assets outside the U.S.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_zkWYCFjMy2T9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. <span id="xdx_826_zYHXuwgIToR6">Net Loss per Share </span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="letter-spacing: -0.05pt">The following table sets forth the computation of basic and diluted net loss per common share attributable to stockholders:</span></p> <p style="font: 9pt/10.8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.4pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zVWLqRC8OVT2" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss per Share (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B7_zwdbUqUAuBRb" style="display: none"> Schedule of potential common shares, presented based on amounts outstanding</td><td> </td> <td colspan="2" id="xdx_498_20260101__20260331_zcmAom1JgOCb"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20250101__20250331_zmcq82XPC7C8"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--NumeratorAbstract_iB_zhNmkduGPJTc" style="vertical-align: bottom"> <td style="font-size: 10pt">Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_pn3n3_zY4NmZoORJZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 13.5pt">Net loss attributable to common stockholders</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; font-size: 10pt; text-align: right">(1,310</td><td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; font-size: 10pt; text-align: right">(770</td><td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--DenominatorAbstract_iB_zUg1HZWajLbl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 13.5pt">Weighted-average common shares outstanding, basic and diluted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331_z6n6drO2jNkh" title="Weighted-average common shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331_zPz4VvyRpi1j" title="Weighted-average common shares outstanding, diluted">172,318,506</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331_z4c3CuEevT3j" title="Weighted-average common shares outstanding, basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331_zR3eAWpyTT4g" title="Weighted-average common shares outstanding, diluted">42,482,376</span></span></td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 13.5pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Net loss per share attributable to common stockholders, <br/>      basic and diluted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20260101__20260331_zR9RGeR5wcha" title="Net loss per share attributable to common stockholders, basic"><span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20260101__20260331_zaEWH6DFhbkl" title="Net loss per share attributable to common stockholders, diluted">(0.01</span></span></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20250101__20250331_z8mvVgtHF9ve" title="Net loss per share attributable to common stockholders, basic"><span id="xdx_908_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20250101__20250331_zzNVaozXmmy8" title="Net loss per share attributable to common stockholders, diluted">(0.02</span></span></td><td style="font-size: 10pt; text-align: left">)</td></tr> </table> <p id="xdx_8AF_zJiqlvmWgNo1" style="font: 9pt/10.8pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 25.4pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4.2pt 0pt 0; text-indent: 25.4pt"><span style="letter-spacing: -0.05pt">The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation</span> of diluted net loss per share for the periods indicated:</p> <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zoX1o4Pdjq07" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss per Share (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8BD_ziVIHswRBZm5" style="display: none; font-size: 12pt; text-align: center">Schedule of potential common shares, presented based on amounts outstanding </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Series A Preferred Stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zGtI9kuNk5de" title="Anti-dilutive securities excluded from computation of earnings per share, amount">15,000,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zgFEUboKHsok" title="Anti-dilutive securities excluded from computation of earnings per share, amount"><span style="-sec-ix-hidden: xdx2ixbrl0746">—</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series C Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zgdJDxs2GPW1" title="Anti-dilutive securities excluded from computation of earnings per share, amount">11,983,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zUsHyyaNyu5e" title="Anti-dilutive securities excluded from computation of earnings per share, amount"><span style="-sec-ix-hidden: xdx2ixbrl0750">—</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Senior Secured Notes, including accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeniorSecuredNotesIncludingAccruedInterestMember_zxMAeTNhyhJj" title="Anti-dilutive securities excluded from computation of earnings per share, amount">154,235</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeniorSecuredNotesIncludingAccruedInterestMember_zgxy7vN4Ofpe" title="Anti-dilutive securities excluded from computation of earnings per share, amount">272,135</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesIncludingAccruedInterestMember_zizQCgYsUez4" title="Anti-dilutive securities excluded from computation of earnings per share, amount">75,000,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Public Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zEtB8kYb5U5" title="Anti-dilutive securities excluded from computation of earnings per share, amount">11,499,982</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zUW1aHBxliYe" title="Anti-dilutive securities excluded from computation of earnings per share, amount">11,499,982</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Private Placement Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivatePlacementWarrantsMember_zut9OUrflk9b" title="Anti-dilutive securities excluded from computation of earnings per share, amount">55,800,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivatePlacementWarrantsMember_ztZVEQO8KJhe" title="Anti-dilutive securities excluded from computation of earnings per share, amount">13,550,000</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedSharesMember_zli8CR0J3Uz6" title="Anti-dilutive securities excluded from computation of earnings per share, amount">1,129,630</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedSharesMember_z2leLehvPtt7" title="Anti-dilutive securities excluded from computation of earnings per share, amount">1,129,630</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zXgGiotMvz4" title="Anti-dilutive securities excluded from computation of earnings per share, amount">39,653,451</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfPZaMGfz2t4" title="Anti-dilutive securities excluded from computation of earnings per share, amount">1,103,451</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z8oe0NMmXV06" title="Anti-dilutive securities excluded from computation of earnings per share, amount">25,000</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpPdMWFLUvT7" title="Anti-dilutive securities excluded from computation of earnings per share, amount">25,000</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331_zp3ZjCdH80Yb" title="Anti-dilutive securities excluded from computation of earnings per share, amount">210,245,298</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331_zBe7ZoiFGOv8" title="Anti-dilutive securities excluded from computation of earnings per share, amount">27,580,198</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_8A1_zyIaOYVvksxk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_pn3n3_zVWLqRC8OVT2" style="font: 12pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss per Share (Details)"> <tr style="vertical-align: bottom"> <td id="xdx_8B7_zwdbUqUAuBRb" style="display: none"> Schedule of potential common shares, presented based on amounts outstanding</td><td> </td> <td colspan="2" id="xdx_498_20260101__20260331_zcmAom1JgOCb"> </td><td> </td><td> </td> <td colspan="2" id="xdx_492_20250101__20250331_zmcq82XPC7C8"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr id="xdx_401_ecustom--NumeratorAbstract_iB_zhNmkduGPJTc" style="vertical-align: bottom"> <td style="font-size: 10pt">Numerator:</td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--NetIncomeLoss_i01_pn3n3_zY4NmZoORJZ5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; font-size: 10pt; text-align: left; padding-bottom: 2.5pt; padding-left: 13.5pt">Net loss attributable to common stockholders</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; font-size: 10pt; text-align: right">(1,310</td><td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 14%; font-size: 10pt; text-align: right">(770</td><td style="width: 1%; padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_409_ecustom--DenominatorAbstract_iB_zUg1HZWajLbl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt">Denominator:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 13.5pt">Weighted-average common shares outstanding, basic and diluted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_906_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20260101__20260331_z6n6drO2jNkh" title="Weighted-average common shares outstanding, basic"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20260101__20260331_zPz4VvyRpi1j" title="Weighted-average common shares outstanding, diluted">172,318,506</span></span></td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span id="xdx_905_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_pid_c20250101__20250331_z4c3CuEevT3j" title="Weighted-average common shares outstanding, basic"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_pid_c20250101__20250331_zR3eAWpyTT4g" title="Weighted-average common shares outstanding, diluted">42,482,376</span></span></td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 13.5pt"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Net loss per share attributable to common stockholders, <br/>      basic and diluted</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20260101__20260331_zR9RGeR5wcha" title="Net loss per share attributable to common stockholders, basic"><span id="xdx_90E_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20260101__20260331_zaEWH6DFhbkl" title="Net loss per share attributable to common stockholders, diluted">(0.01</span></span></td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span id="xdx_907_eus-gaap--IncomeLossFromContinuingOperationsPerBasicShare_pid_c20250101__20250331_z8mvVgtHF9ve" title="Net loss per share attributable to common stockholders, basic"><span id="xdx_908_eus-gaap--IncomeLossFromContinuingOperationsPerDilutedShare_pid_c20250101__20250331_zzNVaozXmmy8" title="Net loss per share attributable to common stockholders, diluted">(0.02</span></span></td><td style="font-size: 10pt; text-align: left">)</td></tr> </table> -1310000 -770000 172318506 172318506 42482376 42482376 -0.01 -0.01 -0.02 -0.02 <table cellpadding="0" cellspacing="0" id="xdx_89B_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_pn3n3_zoX1o4Pdjq07" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Net Loss per Share (Details 1)"> <tr style="vertical-align: bottom"> <td id="xdx_8BD_ziVIHswRBZm5" style="display: none; font-size: 12pt; text-align: center">Schedule of potential common shares, presented based on amounts outstanding </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="6" style="font-size: 8pt; font-weight: bold; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2026</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: center">2025</td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 66%; text-align: left">Series A Preferred Stock</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zGtI9kuNk5de" title="Anti-dilutive securities excluded from computation of earnings per share, amount">15,000,000</span></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 14%; text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesAPreferredStockMember_zgFEUboKHsok" title="Anti-dilutive securities excluded from computation of earnings per share, amount"><span style="-sec-ix-hidden: xdx2ixbrl0746">—</span></span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Series C Preferred Stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zgdJDxs2GPW1" title="Anti-dilutive securities excluded from computation of earnings per share, amount">11,983,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--SeriesCPreferredStockMember_zUsHyyaNyu5e" title="Anti-dilutive securities excluded from computation of earnings per share, amount"><span style="-sec-ix-hidden: xdx2ixbrl0750">—</span></span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Senior Secured Notes, including accrued interest</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeniorSecuredNotesIncludingAccruedInterestMember_zxMAeTNhyhJj" title="Anti-dilutive securities excluded from computation of earnings per share, amount">154,235</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--SeniorSecuredNotesIncludingAccruedInterestMember_zgxy7vN4Ofpe" title="Anti-dilutive securities excluded from computation of earnings per share, amount">272,135</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Convertible promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertiblePromissoryNotesIncludingAccruedInterestMember_zizQCgYsUez4" title="Anti-dilutive securities excluded from computation of earnings per share, amount">75,000,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Public Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zEtB8kYb5U5" title="Anti-dilutive securities excluded from computation of earnings per share, amount">11,499,982</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PublicWarrantsMember_zUW1aHBxliYe" title="Anti-dilutive securities excluded from computation of earnings per share, amount">11,499,982</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Private Placement Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivatePlacementWarrantsMember_zut9OUrflk9b" title="Anti-dilutive securities excluded from computation of earnings per share, amount">55,800,000</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--PrivatePlacementWarrantsMember_ztZVEQO8KJhe" title="Anti-dilutive securities excluded from computation of earnings per share, amount">13,550,000</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Unvested Shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedSharesMember_zli8CR0J3Uz6" title="Anti-dilutive securities excluded from computation of earnings per share, amount">1,129,630</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--UnvestedSharesMember_z2leLehvPtt7" title="Anti-dilutive securities excluded from computation of earnings per share, amount">1,129,630</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock options to purchase common stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zXgGiotMvz4" title="Anti-dilutive securities excluded from computation of earnings per share, amount">39,653,451</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--EmployeeStockOptionMember_zfPZaMGfz2t4" title="Anti-dilutive securities excluded from computation of earnings per share, amount">1,103,451</span></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Restricted stock units</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z8oe0NMmXV06" title="Anti-dilutive securities excluded from computation of earnings per share, amount">25,000</span></td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_908_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_zpPdMWFLUvT7" title="Anti-dilutive securities excluded from computation of earnings per share, amount">25,000</span></td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 12pt; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20260101__20260331_zp3ZjCdH80Yb" title="Anti-dilutive securities excluded from computation of earnings per share, amount">210,245,298</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_c20250101__20250331_zBe7ZoiFGOv8" title="Anti-dilutive securities excluded from computation of earnings per share, amount">27,580,198</span></td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 15000000 11983000 154235 272135 75000000 11499982 11499982 55800000 13550000 1129630 1129630 39653451 1103451 25000 25000 210245298 27580198 <p id="xdx_800_eus-gaap--SubsequentEventsTextBlock_zZLzsJXz3i9l" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. <span id="xdx_82F_z501gt7baDK5">Subsequent Events</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">The Company has evaluated all events subsequent to March 31, 2026 and through June 4, 2026, which represents the date these unaudited condensed consolidated financial statements were available to be issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white">In April 2026, the Company sold and issued to accredited investors a total of <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_ziLW6oIKMRd6" title="Number of shares sold">15,000</span> shares of Series D preferred shares (which are convertible into <span id="xdx_90C_eus-gaap--ProceedsFromConvertibleDebt_pn3n3_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z6Vv6OFYwe7h" title="Proceeds from issuance of convertible notes">34,160,784</span> shares of Common Stock, subject to adjustment) and Warrants to purchase up to <span id="xdx_90E_ecustom--NumberOfWarrantPurchase_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_pd" title="Number of warrant purchase">17,080,392</span> shares of Common Stock (representing 50% warrant coverage on an as-converted basis) for total gross proceeds of $<span id="xdx_90D_ecustom--GrossProceeds_pn3n3_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zmaCO80HI9D2" title="Gross proceeds">15,000</span>. The Company received net proceeds of $<span id="xdx_90B_ecustom--NetProceeds_pn3n3_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zJ3ev1GTRPJe" title="Net proceeds">13,838</span> after deducting commissions and fees. The Company intends to use the net proceeds for working capital and general corporate purposes.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt; color: #212121"><span style="background-color: white"><span id="xdx_907_eus-gaap--CommonStockConversionBasis_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesDPreferredStockMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_zeAUnD8RTX3" title="Common stock conversion basis description">Each share of Series D Convertible Preferred Stock is convertible into 2,278 shares of Common Stock of the Company at the election of the holder, subject to certain adjustments and to beneficial ownership limitations. Each share of Series D Convertible Preferred Stock shall be entitled to vote with the Company’s Common Stock on an as-converted basis, subject to beneficial ownership limitations.</span> The holders of Series D Convertible Preferred Stock shall rank senior to the holders of Common Stock and all other preferred stock with respect to any liquidation, dissolution or winding up of the Company. The Series D Convertible Preferred Stock are not redeemable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt; color: #212121"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white">In connection with the Offering, the Company paid the Placement Agents: (i) a cash fee equal to 6% of the gross proceeds received by the Company in the Offering, and (ii) issued them warrants to purchase 2% of the shares of Common Stock issuable upon conversion of the Series D.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white">As part of the Offering, the Company entered into a Securities Purchase Agreement and Registration Rights Agreement with the investors. The terms of the Securities Purchase Agreement, Series D, Warrants, and Registration Rights Agreement were previously disclosed in the Current Report on Form 8-K filed on April 8, 2026.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><span style="background-color: white">On May 1, 2026, the Company voluntarily filed a registration statement on Form 8-A with the Securities and Exchange Commission to register the Company’s Common Stock pursuant to Section 12(g) of the Securities Exchange Act of 1934 (the Exchange Act”) to enable the Company to become a mandatory “reporting company” subject to the Exchange Act. As a mandatory “reporting company” the Company is now required to make periodic disclosures including, by filing annual reports on Form 10-K, Quarterly Reports on Form 10-Q and must promptly disclose certain important events on a Form 8-K in addition to being subject to other Exchange Act reporting obligations including the proxy rules.</span><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">On April 7, 2026, the Company issued a total of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260401__20260407__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zrR3dUWmXm8j" title="Number of shares issued">15,000,000</span> shares of Common Stock pursuant to the automatic conversion of shares of Series A Convertible Preferred Stock upon completion of certain trigger events.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">On April 30, 2026, the Company issued <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20260401__20260430__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--ConsultantMember_z9nYXx5Or29a" title="Number of shares issued">10,415</span> shares of the Company’s Common Stock to a consultant pursuant to a stock option exercise.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Subsequent to March 31, 2026, the Company granted stock options exercisable into 910,000 shares of its Common Stock to its employees and advisors. The stock options are exercisable at an estimated weighted average price of $0.75 per share.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.7pt">Subsequent to March 31, 2026, the maturity date of the Convertible Promissory Notes (see Note 4) was extended to June 2027.</p> 15000 34160784000 17080392 15000000 13838000 Each share of Series D Convertible Preferred Stock is convertible into 2,278 shares of Common Stock of the Company at the election of the holder, subject to certain adjustments and to beneficial ownership limitations. Each share of Series D Convertible Preferred Stock shall be entitled to vote with the Company’s Common Stock on an as-converted basis, subject to beneficial ownership limitations. 15000000 10415